Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Operating Expenses (2016 - 2025)

Historic Operating Expenses for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to $55.0 million.

  • KalVista Pharmaceuticals' Operating Expenses rose 1356.93% to $55.0 million in Q2 2025 from the same period last year, while for Apr 2025 it was $99.2 million, marking a year-over-year increase of 2161.48%. This contributed to the annual value of $188.0 million for FY2025, which is 3385.67% up from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Operating Expenses stood at $55.0 million for Q2 2025, which was up 1356.93% from $44.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' Operating Expenses' 5-year high stood at $55.0 million during Q2 2025, with a 5-year trough of $33.2 million in Q1 2024.